RxDoctor Payments Data

Mary Wade Diaz, DO

Family Medicine · Virginia Beach, VANPI 1750919130

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 59 payments — averaging $33.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$636
  • Dexcom, Inc.$471
  • Amgen$401
  • Exact Sciences$203
  • Lilly USA, LLC$124
  • Abbott$79
  • plus $56 from 2 others

What the payments were for

  • Food & beverage$1,970100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca16$636
Dexcom, Inc.12$471
Amgen15$401
Exact Sciences9$203
Lilly USA, LLC1$124
Abbott3$79
AbbVie2$36
Stryker1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,970 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$69,572
Medicare patients
132
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$40,360
OzempicSemaglutide24$37,354
EliquisApixaban32$30,961
FarxigaDapagliflozin Propanediol19$21,823
RybelsusSemaglutide14$19,483
JardianceEmpagliflozin15$18,755
JanuviaSitagliptin Phosphate11$17,615
Albuterol Sulfate HfaAlbuterol Sulfate51$1,146
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,046
Atorvastatin Calcium143$915
Omeprazole56$775
Levothyroxine Sodium77$620
Diclofenac Sodium20$546
Losartan Potassium74$501
Amlodipine Besylate101$467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$124$40,36020 claims
AstraZenecaFarxiga$636$21,82319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →